FindTrial
Sign In

ADI-PEG 20 (Arginine deiminase pegylated)

DRUG2 trials

Sponsors

Ludwig Institute for Cancer Research, Sabine Mueller, MD, PhD

Conditions

Diffuse Hemispheric Glioma, H3G34 MutantDiffuse Midline Glioma, H3 K27M-MutantGlioblastomaHigh-Grade Glioma (WHO III-IV)High-grade GliomaSmall Cell Lung Cancer

Phase 1

Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)
Not yet recruitingNCT07389278
Sabine Mueller, MD, PhDDiffuse Hemispheric Glioma, H3G34 Mutant, Diffuse Midline Glioma, H3 K27M-Mutant, Glioblastoma +2
Start: 2027-06-01End: 2035-06-30Target: 97Updated: 2026-09-15

Phase 2

Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
TerminatedNCT01266018
Ludwig Institute for Cancer ResearchSmall Cell Lung Cancer
Start: 2011-01-31End: 2014-01-31Updated: 2022-10-25